Abstract
Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population, largely attributable to cardiovascular disease. Factors that contribute to this increased cardiovascular risk include traditional risk factors, which account for only part of the excess, along with manifestations of the disease itself. RA is characterized by inflammation, which also is a key component in the development of atherosclerosis. Inflammation leads to the activation of endothelial cells, which, through an increase in the expression of leukocyte adhesion molecules, promotes a pro-atherosclerotic environment. Endothelial dysfunction is an early preclinical marker of atherosclerosis, and is commonly found in patients with RA. Several methods are available for the assessment of endothelial function, such as flow-mediated dilatation and laser Doppler flowmetry combined with iontophoresis, each with its own advantages and limitations. Studies have shown that endothelial dysfunction in RA is closely associated with inflammation, and therapeutic reduction of inflammation leads to improvements in endothelial function. As such, assessments of endothelial function could prove to be useful tools in the identification and monitoring of cardiovascular risk in patients with RA. Given the increase in cardiovascular mortality associated with RA, effective management must involve prevention of cardiovascular risk, in addition to control of disease activity and inflammation.
Key Points
-
Rheumatoid arthritis (RA) is associated with increased and premature cardiovascular mortality, which cannot be fully explained by conventional risk factors
-
Manifestations of RA itself, such as the extent of inflammation and severity of the disease, are associated with increased cardiovascular risk in RA
-
Levels of early preclinical markers of atherosclerosis, such as those that reflect endothelial dysfunction, are commonly found to be higher in RA patients than healthy individuals, and are associated with inflammation
-
As several methods can be used to assess endothelial function, selection of the most appropriate tests should be based on an understanding of the advantages and limitations of each technique
-
Assessment of preclinical atherosclerosis could prove useful for the early identification and monitoring of cardiovascular risk in patients with RA
-
Effective management of RA must involve aggressive management of cardiovascular risk, in addition to controlling disease activity and inflammation
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Van Doornum, S., McColl, G. & Wicks, I. P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46, 862–873 (2002).
Myllykangas-Luosujärvi, R. A., Aho, K. & Isomäki, H. A. Mortality in rheumatoid arthritis. Semin. Arthritis Rheum. 25, 193–202 (1995).
Solomon, D. H. et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1608–1612 (2006).
Van Doornum, S., Jennings, G. L. & Wicks, I. P. Reducing the cardiovascular disease burden in rheumatoid arthritis. Med. J. Aust. 184, 287–290 (2006).
Belch, J. J., McSwiggan, S. & Lau, C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology 47 (Suppl. 5), 16–17 (2008).
Watson, D. J., Rhodes, T. & Guess, H. A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J. Rheumatol. 30, 1196–1202 (2003).
Kvalvik, A. G., Jones, M. A. & Symmons, D. P. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand. J. Rheumatol. 29, 29–37 (2000).
Aviña-Zubieta, J. A. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 59, 1690–1697 (2008).
Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303–1307 (2003).
Maradit-Kremers, H. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402–411 (2005).
Goodson, N. J. et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, 2010–2019 (2002).
van Halm, V. P. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 66, 184–188 (2007).
Nielen, M. M. et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50, 2423–2427 (2004).
Nurmohamed, M. T. Cardiovascular risk in rheumatoid arthritis. Autoimmun. Rev. 8, 663–667 (2009).
Rojas-Villarraga, A. et al. Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. Semin. Arthritis Rheum. 38, 71–82 (2008).
Sokka, T. et al. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum. 59, 42–50 (2008).
Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. 33, 2167–2172 (2006).
Panoulas, V. F. et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47, 1286–1298 (2008).
Panoulas, V. F. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46, 1477–1482 (2007).
Dursunoglu, D. et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 25, 241–245 (2005).
Gonzalez, A. et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann. Rheum. Dis. 67, 64–69 (2008).
Escalante, A., Haas, R. W. & del Rincón, I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch. Intern. Med. 165, 1624–1629 (2005).
Chung, C. P. et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 58, 2105–2112 (2008).
DeMaria, A. N. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am. J. Cardiol. 89 (Suppl. 1), 33–38 (2002).
Johnsen, S. P. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. 165, 978–984 (2005).
García-Gómez, C. et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur. J. Clin. Invest. 38, 686–692 (2008).
del Rincón, I., O'Leary, D. H., Haas, R. W. & Escalante, A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 50, 3813–3822 (2004).
Davis, J. M. 3rd et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 56, 820–830 (2007).
Ridker, P. M. et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281, 1817–1821 (1999).
Roubenoff, R. et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 40, 718–722 (1997).
van Ede, A. E. et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41, 658–665 (2002).
Choi, H. K., Hernán, M. A., Seeger, J. D., Robins, J. M. & Wolfe, F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173–1177 (2002).
Gonzalez-Gay, M. A. et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57, 125–132 (2007).
Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836–843 (2000).
Ku, I. A., Imboden, J. B., Hsue, P. Y. & Ganz, P. Rheumatoid arthritis: a model of systemic inflammation driving atherosclerosis. Circ. J. 73, 977–985 (2009).
Gonzalez-Juanatey, C. et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57, 287–293 (2007).
Salmon, J. E. & Roman, M. J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am. J. Med. 121 (Suppl. 1), S3–S8 (2008).
Dixon, W. G. & Symmons, D. P. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann. Rheum. Dis. 66, 1132–1136 (2007).
Gonzalez, M. A. & Selwyn, A. P. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am. J. Med. 115 (Suppl. 8A), 99S–106S (2003).
Devaraj, S., Yun, J. M., Adamson, G., Galvez, J. & Jialal, I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc. Res. 84, 479–484 (2009).
Gonzalez-Juanatey, C. et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am. J. Med. 114, 647–652 (2003).
Methe, H. & Weis, M. Atherogenesis and inflammation--was Virchow right? Nephrol. Dial. Transpl. 22, 1823–1827 (2007).
Mäki-Patäjä, K. M. et al. Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int. J. Cardiol. 129, 399–405 (2008).
Ito, A. et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092–3095 (1999).
Khan, F. et al. Impaired microvascular function in normal children: effects of adiposity and poor glucose handling. J. Physiol. 551, 705–711 (2003).
Halcox, J. P. et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653–658 (2002).
Kumeda, Y. et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1489–1497 (2002).
Gonzalez-Gay, M. A. et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol. 32, 1219–1223 (2005).
del Rincón, I. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subject. Arthritis Rheum. 48, 1833–1840 (2003).
del Rincón, I., Freeman, G. L., Haas, R. W., O'Leary, D. H. & Escalante, A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 52, 3413–3423 (2005).
Mäki-Patäjä, K. M. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114, 1185–1192 (2006).
Galarraga, B., Khan, F., Kumar, P., Pullar, T. & Belch, J. J. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 48, 1418–1423 (2009).
Ludmer, P. L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046–1051 (1986).
Khan, F. & Coffman, J. D. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 89, 1183–1188 (1994).
Anderson, T. J. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235–1241 (1995).
Shechter, M. et al. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int. J. Cardiol. 134, 52–58 (2009).
Gokce, N. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol. 41, 1769–1775 (2003).
Karatzis, E. N. et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am. J. Cardiol. 98, 1424–1428 (2006).
Staniloae, C. et al. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 108, 164–169 (2007).
Charbonneau, F. et al. Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197, 420–427 (2008).
Turner, J., Belch, J. J. & Khan, F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc. Med. 18, 109–116 (2008).
Arosio, E. et al. Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J. Hypertens. 25, 1273–1278 (2007).
Newton, D. J., Khan, F. & Belch, J. J. Assessment of microvascular endothelial function in human skin. Clin. Sci. 101, 567–572 (2001).
Khan, F., Elhadd, T. A., Greene, S. A. & Belch, J. J. Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care 23, 215–220 (2000).
Ijzerman, R. G. et al. Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur. J. Clin. Invest. 33, 536–542 (2003).
Khan, F., Patterson, D., Belch, J. J., Hirata, K. & Lang, C. C. Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. Clin. Sci. 115, 295–300 (2008).
Huang, A. L. et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler. Thromb. Vasc. Biol. 27, 2113–2119 (2007).
Wilkinson, I. B. et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler. Thromb. Vasc. Biol. 22, 147–152 (2002).
Chowienczyk, P. J. et al. Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J. Am. Coll. Cardiol. 34, 2007–2014 (1999).
Belch, J. J. et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 95, 2027–2031 (1997).
Hope, S. A. & Meredith, I. T. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern. Med. J. 33, 450–462 (2003).
McLaren, M., Elhadd, T. A., Greene, S. A. & Belch, J. J. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin. Appl. Thromb. Hemost. 5, 21–24 (1999).
Felmeden, D. C., Blann, A. D., Spencer, C. G., Beevers, D. G. & Lip, G. Y. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul. Fibrinolysis 14, 425–431 (2003).
Folsom, A. R. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100, 736–742 (1999).
Whincup, P. H. et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur. Heart J. 23, 1764–1770 (2002).
Avouac, J., Uzan, G., Kahan, A., Boileau, C. & Allanore, Y. Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine 75, 131–137 (2008).
Ablin, J. N. et al. Effect of anti-TNFα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79, 2364–2369 (2006).
Hannawi, S., Marwick, T. H. & Thomas, R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res. Ther. 11, R51 (2009).
Vaudo, G. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis. 63, 31–35 (2004).
Hänsel, S., Lässig, G., Pistrosch, F. & Passauer, J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170, 177–180 (2003).
Kerekes G. et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398–406 (2008).
Stamatelopoulos, K. S. et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler. Thromb. Vasc. Biol. 29, 1702–1708 (2009).
Gonzalez-Juanatey, C. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum. 51, 447–450 (2004).
Hürlimann, D. et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184–2187 (2002).
Bosello, S. et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 27, 833–839 (2008).
Gonzalez-Juanatey, C. et al. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24, 309–312 (2006).
Bilsborough, W. et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26, 1125–1131 (2006).
Sidiropoulos, P. I. et al. Sustained improvement of vascular endothelial function during anti-TNFα treatment in rheumatoid arthritis patients. Scand. J. Rheumatol. 38, 6–10 (2009).
Gonzalez-Juanatey, C. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum. 59, 1821–1824 (2008).
Flammer, A. J. et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117, 2262–2269 (2008).
Syngle, A., Vohra, K., Kaur, L. & Sharma, S. Effects of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand. J. Rheumatol. 38, 15–22 (2009).
Mäki-Petäjä, K. M. et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 50, 852–858 (2007).
Datta, D., Ferrell, W. R., Sturrock, R. D., Jadhav, S. T. & Sattar, N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192, 391–395 (2007).
Galarraga, B., Khan, F., Kumar, P., Pullar, T. & Belch, J. J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 47, 1780–1784 (2008).
Galarraga, B., Belch, J. J. C., Pullar, T., Ogston, S. & Khan, F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J. Rheumatol. doi:10.3899/jrheum.090417.
Lau, C. S., McLaren, M., Hanslip, J., Kerr, M. & Belch, J. J. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann. Rheum. Dis. 52, 643–649 (1993).
McLaren, M., Alkaabi, J., Connacher, M., Belch, J. J. & Valenete, E. Activated factor XII in rheumatoid arthritis. Rheumatol. Int. 22, 182–184 (2002).
Klimiuk, P. A., Fiedorczyk, M., Sierakowski, S. & Chwiecko, J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 36, 345–350 (2007).
Cobankara, V. et al. Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clin. Rheumatol. 23, 430–434 (2004).
Galarraga, B., Mclaren, M., Kennedy, G. & Belch, J. J. E-selectin in rheumatoid arthritis [abstract 19]. Rheumatology (Oxford) 45 (Suppl. 1), i32 (2006).
McEntegart, A. et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40, 640–644 (2001).
Wållberg-Jonsson, S., Cederfelt, M. & Rantapää Dahlqvist, S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J. Rheumatol. 27, 71–75 (2000).
Peters, M. J. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325–331 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Khan, F., Galarraga, B. & Belch, J. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol 6, 253–261 (2010). https://doi.org/10.1038/nrrheum.2010.44
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.44
This article is cited by
-
A systematic review and meta-analysis of circulating adhesion molecules in rheumatoid arthritis
Inflammation Research (2024)
-
Patient with rheumatoid arthritis with deep vein thrombosis presenting as a calf strain: a case report
Journal of Medical Case Reports (2020)
-
A prospective, longitudinal monocentric study on laser Doppler imaging of microcirculation: comparison with macrovascular pathophysiology and effect of adalimumab treatment in early rheumatoid arthritis
Rheumatology International (2020)
-
Association between urinary sodium and potassium excretion and blood pressure and inflammation in patients with rheumatoid arthritis
Clinical Rheumatology (2018)
-
Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation
Arthritis Research & Therapy (2017)